ArticleFrontiers in immunology2026
KA101 outperforms other clinical adjuvants in inducing balanced Th1/Th2 immunity and robust B cell responses to varicella-zoster virus glycoprotein E.
Yaru Quan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.